A health care attorney clarifies how amendments to the HIPAA Privacy Rule bear on the recruitment of clinical trials subjects.
On 14 August 2002, the U.S. Department of Health & Human Services approved final amendments to the so-called Privacy Rule, the privacy regulations issued by HHS in December 2000. With regard to research recruitment and the need for an authorization for disclosure of protected health information to third parties, the language in the preamble to the final amendments is intended to clarify the following: Although 45 CFR 164.512(i)(1)(ii) allows use or disclosure of protected health information for research preparatory activities, including recruitment, on the hospitals site, the protected health information may not be removed from the hospitals site by the researcher for such activities without the patients authorization or waiver, or without alteration thereof by the institutional review board (IRB).
When can researchers view protected information about patients? Under 45 CFR 164.512(i)(1)(ii), a hospital may permit researchers to view protected health information about its patients for purposes of the researcher preparing the research protocol and recruiting subjects provided that the researcher demonstrates, either in writing or orally, that
When can researchers record and remove protected information? The researcher may record and remove protected health information from the hospitals premises only if the hospital either waives or modifies authorization requirements (and appropriately documents this) or obtains an authorization from the patient. Alternatively, the researcher may remove de-identified information, or the hospital may disclose a limited data set to the researcher, provided the hospital and the researcher enter into a data use agreement relating to the limited data set.
Guidelines for Obtaining Informed Consent for Clinical Research
November 2nd 2003Informed consent is a process, not just a form signed by prospective study subjects. Documents such as the Code of Federal Regulations describe the elements of informed consent, but lack substantive direction on the process of obtaining consent.1-2 The purpose of this article is to provide guidelines for obtaining informed consent. This guide can be useful to anyone involved in clinical research, particularly newcomers to the industry.
A Clinical Development Solution Tailored for Biopharmaceutical Companies
November 1st 2003The rapid evolution of the biopharmaceutical industry has lead more and more companies to focus on the clinical development of their drug candidates, thus presenting the challenge of selecting the optimal strategy for conducting their clinical programs. Typically, biopharmaceutical companies have had three options: out-licensing their product, setting up their own clinical development operations, or outsourcing the clinical development to contract research organizations (CROs).